McSAF Inside® Oncology selected in the Top100 of start-up to fund in 2021

McSAF Inside® Oncology, with its drug development project in oncology, was selected along with 99 others start-up as a company to fund in 2021 by the newspaper Challenges. It underlines the relevance of our value of proposal.
Go check the sum-up and article published in March 21.
https://www.challenges.fr/start-up/details/mcsaf-inside-oncology_1213
https://www.challenges.fr/start-up/mcsaf-des-produits-innovants-au-service-des-patients_756458

Press Release: The European Patent Office has granted McSAF a patent for DAR 4 antibody-drug conjugates technology

Tours, France – 25/02/2021- The European Patent Office (EPO) has granted the patent number EP3521314 on the McSAF Inside® technology to access DAR 4 antibody-drug conjugates, an emerging class of targeted medicines. This completes the portfolio of granted patents in France (FR3008408), Japan (JP6533222) and United States of America (US10307488). This is an essential asset for McSAF to become a key player in the bioconjugation field in the future.

Antibody-drug conjugates (ADCs) are an emerging class of targeted medicines. With nine drugs available on the market, five of them approved in the last two years underlining the expansion of the field. New technologies for improved and safer ADCs are a major challenge nowadays and McSAF Inside® technology allows to obtain homogeneous, more stable drugs for high value developments in and outside oncology.

McSAF recrute un(e) Technicien(ne) R&D

Intéressé par ce poste?

Suivez ce lien :

Meet us at next World ADC Summit, London, 5-6th March 2019

McSAF’s team will be attending next World ADC Summit Europe, London.

We will present our last results on patented technology.

Looking forward to seeing you there

Meeting request : contact@mcsaf.fr

Meet us at 5th Antibody Industrial Symposium, June 27-28, Tours – France

McSAF is presenting at the 5th Antibody Industrial Summit, co-organized by MAbDesign, MAbImprove & Polepharma, June 27-28, in Tours, France.

More information & B2B request meeting on … http://ais2017.fr

Meet us at next World ADC Summit, Berlin, 20-22th Feb

McSAF’s team will be attending next World ADC Summit Europe, Berlin, .

World ADC Summit is the main event dedicated to Antibody Drug Conjugates in Europe. More information …

Will be participating :

  • Marie-Claude Viaud-Massuard, Scientific Director
  • David Bonnafous, Chief Operating Officer, in charge of Business Development & Strategic Partnerships,
  • Christine Baltus, R&D Director

Looking forward to seeing you there

Meeting request : contact@mcsaf.fr.

MC Viaud, McSAF CSO, presenting new ADC-linker technologies at Immunoconjugates for Personalised Medicine, Nantes, 9th Feb

Marie-Claud VIAUD-MASSUARD, McSAF Chief Scientific Officer & co-founder will be given a talk on new ADC-linker technologies on next meeting dedicated to “Immunoconjugates for personalised medicine”, co-organized par MAbDesign & Atlanpole Biotherapies – 9th fev. Nantes. More information : https://lnkd.in/d7QZK25

Meet McSAF’s team at next International Partnering Conference BIO-Europe, Koehln, Nov 07-09, 2016

McSAF’s team is pleased to announce its attendance at Bio-Europe from November 7-9, 2016 in Cologne, Germany.
BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry which hosts more than 3,500 professionals and 1,800 companies from over 50 countries. The conference annually attracts leading dealmakers from biotech, pharma and finance.

David Bonnafous, Chief Operating Officer, in charge of Business Development & Strategic Alliances, will attend the conference.
We would be pleased to meet with you during BIO-Europe. To schedule a meeting, please send an email to contact@mcsaf.fr.

We look forward to hearing from you!